Last reviewed · How we verify
NCT05366699
LYMPHA Procedure for the Prevention of Lymphedema After Axillary Lymphadenectomy
NA trial testing axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA) in Lymphedema, Breast Cancer in 80 participants. Currently enrolling.
1 June 2026
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 10 September 2021 |
| Primary completion | 1 June 2026 |
| Estimated completion | 1 June 2030 |
| Sites | 1 location across United States |
Drugs / interventions tested
- axillary lymphadenectomy with immediate lymphatic reconstruction (LYMPHA)
- Axillary lymphadenetomy alone
- axillary lymphadenectomy with soft tissue reinforcement
Conditions studied
- Lymphedema, Breast Cancer — all drugs for Lymphedema, Breast Cancer →
- Lymphedema — all drugs for Lymphedema →
Sponsor
Stanford University
Who can join
Adults 18 to 75, female only, with Lymphedema, Breast Cancer or Lymphedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lymphedema is a chronic, progressive, and debilitating condition that occurs with disruption or obstruction of the lymphatic system, which commonly occurs a result of breast cancer therapy. The purpose of this study is to determine if the use of a low risk lymphatic reconstruction procedure at the time of axillary lymph node dissection will reduce the risk of developing lymphedema. Additionally, to determine if this procedure improves objective outcomes of lymphedema and patient quality of life
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Is Immediate Lymphatic Reconstruction on Breast Cancer Patients Oncologically Safe? A Preliminary Study.
Lin YS, Kuan CH, Lo C, Tsai LW, et al · · 2023 · cited 9× · PMID 37941816 · DOI 10.1097/gox.0000000000005385 -
Mitigating Breast-Cancer-Related Lymphedema-A Calgary Program for Immediate Lymphatic Reconstruction (ILR).
Deban M, McKinnon JG, Temple-Oberle C. · · 2023 · cited 5× · PMID 36826080 · DOI 10.3390/curroncol30020119 -
Demystifying vascularized lymph node transfers and lymphatico-venous anastomoses.
Almadani Y, Davison P, Efanov JI, Kokosis G, et al · · 2024 · cited 2× · PMID 38304897 · DOI 10.21037/atm-23-132
Verify or expand the search:
- PubMed search for NCT05366699
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lymphedema, Breast Cancer
Currently open trials in the same condition.
- NCT07257679 — Gentle Touch for Post-Mastectomy Lymphedema · Phase 4 · recruiting
- NCT06302361 — Lymphovenous Anastomosis for Breast Cancer Lymphedema · NA · active not recruiting
- NCT05441943 — Lymphaticovenous Anastomosis as Treatment for Lymphedema · NA · active not recruiting
- NCT05601037 — LymphoVenous Anastomosis to Prevent Breast Cancer Related Lymphedema · NA · recruiting
- NCT04888975 — A Non-randomized, Open-Label Study to Evaluate the Safety and Effectiveness of the Dayspring Technology for Patients Wit · NA · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05366699 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 29 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05366699.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing